Louisbourg Investments Inc. Grows Holdings in Becton, Dickinson and Company (NYSE:BDX)

Louisbourg Investments Inc. raised its position in Becton, Dickinson and Company (NYSE:BDX) by 12.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 34,765 shares of the medical instruments supplier’s stock after purchasing an additional 3,855 shares during the period. Becton, Dickinson and Company accounts for 1.9% of Louisbourg Investments Inc.’s holdings, making the stock its 12th biggest position. Louisbourg Investments Inc.’s holdings in Becton, Dickinson and Company were worth $7,887,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the company. State Street Corp increased its position in shares of Becton, Dickinson and Company by 0.8% during the third quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after acquiring an additional 106,616 shares during the last quarter. Geode Capital Management LLC boosted its position in Becton, Dickinson and Company by 1.8% in the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock worth $1,510,050,000 after purchasing an additional 111,101 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Becton, Dickinson and Company by 31.0% during the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after purchasing an additional 673,568 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This trade represents a 8.01 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the transaction, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BDX. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Trading Down 0.0 %

Shares of BDX stock opened at $229.50 on Wednesday. The stock has a market capitalization of $66.56 billion, a price-to-earnings ratio of 38.12, a PEG ratio of 1.65 and a beta of 0.40. The company’s fifty day simple moving average is $232.36 and its two-hundred day simple moving average is $233.94. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.41 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has initiated a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.